Schizophrenia Research
Volume 98, Issue 1 , Pages 66-78 , January 2008

In vitro and in vivo demonstration of risperidone implants in mice

  • C. Rabin

      Affiliations

    • Stanley Center for Experimental Therapeutics, Division of Neuropsychiatry, Department of Psychiatry University of Pennsylvania, United States
    • ,
  • Y. Liang

      Affiliations

    • Stanley Center for Experimental Therapeutics, Division of Neuropsychiatry, Department of Psychiatry University of Pennsylvania, United States
    • ,
  • R.S. Ehrlichman

      Affiliations

    • Stanley Center for Experimental Therapeutics, Division of Neuropsychiatry, Department of Psychiatry University of Pennsylvania, United States
    • ,
  • A. Budhian

      Affiliations

    • Department of Materials Science and Engineering, University of Pennsylvania, United States
    • ,
  • K.L. Metzger

      Affiliations

    • Stanley Center for Experimental Therapeutics, Division of Neuropsychiatry, Department of Psychiatry University of Pennsylvania, United States
    • ,
  • C. Majewski-Tiedeken

      Affiliations

    • Stanley Center for Experimental Therapeutics, Division of Neuropsychiatry, Department of Psychiatry University of Pennsylvania, United States
    • ,
  • K.I. Winey

      Affiliations

    • Department of Materials Science and Engineering, University of Pennsylvania, United States
    • ,
  • S.J. Siegel

      Affiliations

    • Stanley Center for Experimental Therapeutics, Division of Neuropsychiatry, Department of Psychiatry University of Pennsylvania, United States
    • Corresponding Author InformationCorresponding author. Division of Neuropsychiatry, Stanley Center for Experimental Therapeutics in Psychiatry, Translational Research Laboratories Rm. 2223, 125 South 31st St., University of Pennsylvania, Philadelphia, PA 19104, United States. Tel.: +1 215 573 0278; fax: +1 215 573 2041.

Received 11 May 2007 ,Revised 30 July 2007 ,Accepted 1 August 2007.

References 

  1. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Safety. 1994;10:464–479
  2. Bloch YMS, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?. J. Clin. Psychiatry. 2001;62:855–859
  3. Boutros N, Korzyukov O, Jansen B, Feingold A, Bell M. Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Res. 2004;126:203–215
  4. Connolly PM, Maxwell C, Liang Y, Kahn JB, Kanes SJ, Abel T, et al. The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem. Res. 2004;29:1179–1188
  5. de Oliveria IR, Miranda-Scippa AM, de Sena EP, Pereira EL, Ribeiro MG, de Castro-e-Silva E, et al. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J. Clin. Pharm. Ther. 1996;21:349–358
  6. Du LJC, Chi Qiang, Qie Jiankun, Liu Yan, Mei Xingguo. Biodegradable PLGA microspheres as a sustained release system for a New Luteinizing Hormone-Releasing Hormone (LHRH) antagonist. Chem. Pharm. Bull. 2006;54:1259
  7. Ereshefsky L, Mannaert E. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J. Clin. Psychiatry. 2003;64:18–23
  8. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R&D. 2005;6:129–137
  9. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R&D. 2005;6:129–137
  10. Fulzele SV, Satturwar PM, Dorle AK. Novel biopolymers as implant matrix for the delivery of ciprofloxacin: biocompatibility, degradation, and in vitro antibiotic release. J. Pharm. Sci. 2007;96:132–144
  11. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry. 2004;161:692–699
  12. Gould TJ, Bizily SP, Tokarczyk J, Kelly MP, Siegel SJ, Kanes SJ, et al. Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha. Neuropsychopharmacology. 2004;29:494–501
  13. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J. Psychopharmacol. 2004;18:375–383
  14. Hyon S. Biodegradable poly (lactic acid) microspheres for drug delivery systems. Yonsei Med. J. 2000;41:720–734
  15. Irani F, Dankert M, Brensinger C, Bilker WB, Nair SR, Kohler CG, et al. Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine. Neuropsychopharmacology. 2004;29:960–968
  16. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry. 2006;63:1079–1087
  17. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J. Clin. Psychiatry. 2006;67(Suppl 5):9–14
  18. Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr. 2006;11:1–7(quiz 7–8)
  19. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur. Neuropsychopharmacol. 1998;8:55–66
  20. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry. 2003;160:1125–1132
  21. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003;305:625–631
  22. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry. 2004;161:985–995
  23. Kitchell JWD. Poly(lactic/glycolic acid) biodegradable drug–polymer matrix systems. Methods Enzymol. 1985;112:436–448
  24. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am. J. Psychiatry. 2005;162:1010–1012
  25. Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin. Ther. 2004;26:1994–2002
  26. Lambert TJR, Castle DJ. Pharmacological approaches to the management of schizophrenia. Med. J. Aust. 2003;178:S57–S61
  27. Lieberman JA. Comparative effectiveness of antipsychotic drugs: a commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch. Gen. Psychiatry. 2006;63:1069–1072
  28. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353:1209–1223
  29. Maxwell CR, Liang Y, Weightman BD, Kanes SJ, Abel T, Gur RE, et al. Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology. 2004;29:739–746
  30. Medori R, Mannaert E, Grunder G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur. Neuropsychopharmacol. 2006;16:233–240
  31. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum. Psychopharmacol. 2006;21:529–532
  32. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state medicaid program. Psychiatr. Serv. 2003;54:719–723
  33. Metzger KL, Maxwell CR, Liang Y, Siegel SJ. Effects of Nicotine Vary Across Two Auditory Evoked Potentials in the Mouse. Biol. Psychiatry. 2006;61:23–30
  34. Metzger KL, Shoemaker JM, Kahn JB, Maxwell CR, Liang Y, Tokarczyk J, et al. Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. Psychopharmacology (Berl). 2007;190:201–211
  35. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur. J. Pharmacol. 2006;540:87–90
  36. Nasrallah HA, Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J. Psychopharmacol. 2006;20:57–61
  37. Okada HTH. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 1995;12:1–99
  38. Olesen OVL, Rasmus W, Thomsen Erik, Bruun Troels, Viftrup Jens Emil, Linnet Kristian. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther. Drug Monit. 1998;20:380–384
  39. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am. J. Psychiatry. 2006;163:396–401
  40. Sabel BA, Dominiak P, Hauser W, During MJ, Freese A. Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats. J. Pharmacol. Exp. Ther. 1990;255:914–922
  41. Schliecker G, Schmidt C, Fuchs S, Ehinger A, Sandow J, Kissel T. In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis. J. Control. Release. 2004;94:25–37
  42. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, et al. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology. 2006;31:506–515
  43. Turner MS, Stewart DW. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J. Psychopharmacol. 2006;20:20–37
  44. Umbricht D, Vyssotky D, Latanov A, Nitsch R, Brambilla R, D'Adamo P, et al. Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans. Brain Res. 2004;1019:189–200
  45. Valenstein MBF, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr. Bull. 2004;30:255–264
  46. Wang G, Tucker IG, Roberts MS, Hirst LW. In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(d,l-lactide-co-glycolide). Pharm. Res. 1996;13:1059–1064
  47. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am. J. Psychiatry. 2002;159:1653–1664

PII: S0920-9964(07)00335-0

doi: 10.1016/j.schres.2007.08.003

Schizophrenia Research
Volume 98, Issue 1 , Pages 66-78 , January 2008

Article Tools

* Image Usage & Resolution